Education
About Us
Working with TipRanks
Follow Us
Traws Pharma (TRAW)
NASDAQ:TRAW
TRAW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.52 - $19.44
Previous CloseN/A
Volume35.69K
Average Volume (3M)99.15K
Market Cap
$10.15M
Enterprise Value$11.08M
Total Cash (Recent Filing)$67.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.53
Next Earnings
May 15, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)101.35
Shares Outstanding5,073,790
10 Day Avg. Volume48,705
30 Day Avg. Volume99,153
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)38.02
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit52.76
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$6.00Price Target Upside292.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Traws Pharma News
PremiumCompany Announcements
Traws Pharma Appoints New Chairman Amid Leadership Changes
PremiumCompany Announcements
Traws Pharma Reports 2024 Results and Strategic Progress
PremiumCompany Announcements
Traws Pharma Reports 2024 Financial Results and CEO Change
PremiumCompany Announcements
Traws Pharma Announces CEO Transition and Investor Update
---
Ownership Overview
55.35% Insiders
0.42% Mutual Funds
21.45% Other Institutional Investors
22.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $1.52 and its highest was $19.44 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $10.15M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is May 15, 2025 which is in 20 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Mar 31, 2025. The company reported $101.35 earnings per share for the quarter, beating the consensus estimate of -$9.55 by $110.9.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 5,073,790 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of $101.35 in its last earnings report, beating expectations of -$9.55. Following the earnings report the stock price went down -4.167%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
---
Traws Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (292.16% Upside)
$6.00 (292.16% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.82%
12-Months-Change
Fundamentals
Return on Equity
-2255.45%
Trailing 12-Months
Asset Growth
10.05%
Trailing 12-Months
Company Description
Traws Pharma
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
---
TRAW Earnings Call
Q4 2025
0:00 / 0:00
---
TRAW Stock 12 Month Forecast
Average Price Target
$6.00
▲(292.16% Upside)
Technical Analysis
Best Analysts Covering TRAW
1 Year
1 Year Success Rate
2/18 ratings generated profit
1 Year Average Return
-42.88%
reiterated a buy rating 5 months ago
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -42.88% per trade.
---